Research Papers:
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2100 views | HTML 12888 views | ?
Abstract
Lu Qian Wang1, Kwan Yeung Wong1, Zhen Hai Li1, Chor Sang Chim1
1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
Correspondence to:
Chor Sang Chim, email: [email protected]
Keywords: BM742401, lncRNA, tumor suppressor, DNA methylation, chronic lymphocytic leukemia
Received: January 20, 2016 Accepted: September 20, 2016 Published: September 26, 2016
ABSTRACT
BM742401 is a tumor suppressor lncRNA downregulated in gastric cancer. As the promoter region and the entire transcript are embedded in a CpG island, we postulated that BM742401 is a tumor suppressor lncRNA inactivated by DNA methylation in chronic lymphocytic leukemia (CLL). The promoter of BM742401 was unmethylated in normal controls including three each of normal bone marrow, peripheral blood buffy coats, and CD19-sorted peripheral B-cells, but methylated in four (57.1%) CLL cell lines. Methylation of BM742401 correlated inversely with expression. In the completely methylated WAC3CD5+ CLL cells, 5-Aza-2′-deoxycytidine treatment led to promoter demethylation and re-expression of BM742401 transcript. Functionally, stable overexpression of BM742401 resulted in inhibition of cellular proliferation and enhanced apoptosis through caspase-9-dependent intrinsic but not caspase-8-dependent extrinsic apoptosis pathway, suggesting a tumor suppressor role of BM742401 in CLL. In primary CLL samples, methylation of BM742401 was detected in 43/98 (43.9%) of patients. Moreover, among CLL patients with standard-risk cytogenetic aberrations, methylation of BM742401 correlated with advanced Rai stage (≥ stage 2)(P = 0.002). Furthermore, BM742401 methylation was associated with miR-129-2 methylation (P = 0.05). BM742401 is a tumor suppressor lncRNA frequently methylated in CLL. The mechanism of BM742401 as a tumor suppressor warrants further studies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12252